21 March 2026
: Case report 
Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report
Unusual or unexpected effect of treatment, Patient complains / malpractice, Unexpected drug reaction, Clinical situation which can not be reproduced for ethical reasons, Rare coexistence of disease or pathology
Yusuke Sanji ABCDEFG 1*, Isao Matsushita ADE 2, Eiji Takahashi A 1, Makoto Fukui A 1, Hironori Kitajima
A 1, Ayumi Kaneuji A 1
DOI: 10.12659/AJCR.950915
Am J Case Rep 2026; 27:e950915
Figure 1 Timeline of the clinical courseClinical course of pharmacologic treatment and disease activity in rheumatoid arthritis (RA). Temporal changes in C-reactive protein (CRP) and the Simplified Disease Activity Index (SDAI) are shown in relation to adjustments in antirheumatic therapy. After initiation of upadacitinib (UPA), CRP levels and SDAI decreased progressively, indicating improved control of rheumatoid arthritis disease activity.